RxDoctor Payments Data

Marc Guttman, DO

Urology · Naples, FLNPI 1972708154

Payments from drug & device makers

$17,755in general payments, 2019–2025

Across 368 payments — averaging $48.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$3K
  • Astellas Pharma US Inc$3K
  • Neotract Inc.$2K
  • Axonics, Inc.$1K
  • Johnson & Johnson$1K
  • Bayer$905
  • plus $6K from 40 others

What the payments were for

  • Consulting fees$7454%
  • Speaking & faculty fees$2,35013%
  • Travel & lodging$1,6849%
  • Food & beverage$12,73172%
  • Education$2451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,755 in reported general payments places this provider in the 80th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$774,223
Medicare patients
1,984
Services billed
17,757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide25$335,699
OrgovyxRelugolix97$294,298
GemtesaVibegron155$184,675
MyrbetriqMirabegron61$78,193
Dutasteride99$3,561
Tadalafil47$3,261
Alfuzosin Hcl ErAlfuzosin Hcl88$2,117
Silodosin12$1,787
Estradiol22$1,652
Tamsulosin Hcl107$1,582
Cefpodoxime Proxetil25$1,130
Methenamine Hippurate21$1,116
Finasteride48$1,105
Solifenacin Succinate19$1,099
Doxycycline Hyclate57$934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$397$478,973252 claims
Astellas Pharma US IncXtandi, Myrbetriq$3,009$413,89386 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 urology providers in Florida.

Other urology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →